Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

<ns4:p>Seasonal influenza has a significant annual global impact. Current influenza vaccines work by inducing strain-specific antibodies against the highly polymorphic surface proteins of the influenza virus and need to be redesigned every year, increasing their cost and limiting availability. There is a demand for a more efficacious vaccine, particularly in older adults in which the current vaccines show poor efficacy. The aim is to investigate a novel vaccine, MVA-NP+M1, which targets T cell responses to the nucleoprotein and matrix 1 core proteins of the influenza virus A, which are highly conserved,<ns4:bold>  </ns4:bold>and therefore may provide long protection against a broad range of influenza strains.</ns4:p><ns4:p> INVICTUS is a phase IIb study to determine the safety and efficacy of candidate <ns4:underline>IN</ns4:underline>fluenza <ns4:underline>V</ns4:underline>accine MVA-NP+M1 in combination with licensed <ns4:underline>I</ns4:underline>na<ns4:underline>CT</ns4:underline>ivated infl<ns4:underline>U</ns4:underline>enza vaccine in adult<ns4:underline>S</ns4:underline> aged 65 years and above is a randomised, participant-blinded, placebo-controlled, multi-centre phase IIb efficacy study planned for 2030 volunteers aged 65 and over, in primary care. The primary objective is to assess the efficacy of MVA-NP+M1 co-administered with licensed inactivated quadrivalent influenza vaccine in adults ≥65 years. Participants complete daily diaries to record solicited and unsolicited events in the first four weeks post vaccination, and influenza-like illness (ILI) symptoms and severity throughout the influenza season.</ns4:p><ns4:p> We hypothesise an improvement in the primary outcome, a reduction in the average number of days spent with moderate or severe influenza-like illness during periods of influenza circulation, in the group administered with MVA-NP+M1, compared to those in the control group.</ns4:p><ns4:p> <ns4:bold>Registration: </ns4:bold>ClinicalTrials.gov identifier <ns4:ext-link xmlns:ns3="http://www.w3.org/1999/xlink" ext-link-type="uri" ns3:href="https://clinicaltrials.gov/ct2/show/NCT03300362">NCT03300362</ns4:ext-link>.</ns4:p><ns4:p> <ns4:bold>Protocol version:</ns4:bold> INVICTUS Protocol v3.0, 08 June06 2018.</ns4:p>

Original publication

DOI

10.12688/f1000research.19090.1

Type

Journal article

Journal

F1000Research

Publisher

F1000 Research Ltd

Publication Date

23/05/2019

Volume

8

Pages

719 - 719